Celebrating 20 Years of IP Excellence

This image depicts Tablets of different colors. This image is relevant as there is a Patent Infringement dispute between Aurobindo Pharma and Astrazeneca. Click on the image for more information.

Astrazeneca to retain Sweetness of Onglyza

Aurobindo Pharma, USA, has been dragged to the Court for patent infringement by Astrazeneca. The suit filed is against the ANDA (Abbreviated New Drug Application) filed by Aurobindo Pharma with the USFDA with regard to seeking the market approval for Saxagliptin hydrochloride tablets before the expiry of its US patent. Aurobindo Pharma plans to market the generic versions of Saxagliptin hydrochloride tablets of 2.5 mg and 5 mg strengths. Astrazeneca is the sole marketer of Saxagliptin hydrochloride tablets having got…

Read more